The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation In Vitro

The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation In Vitro

The retinoid X receptor agonist bexarotene promotes remyelination in patients with multiple sclerosis. Murine studies have also demonstrated that RXR agonists have anti-inflammatory effects by enhancing the ability of all-trans-retinoic acid (atRA) to promote T-regulatory cell (Treg) induction and r...

Full description

Bibliographic Details
Main Authors: Christopher M. Gaunt, Daniel B. Rainbow, Ruairi J. Mackenzie, Lorna B. Jarvis, Hani S. Mousa, Nicholas Cunniffe, Zoya Georgieva, J. William Brown, Alasdair J. Coles, Joanne L. Jones
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Immunology
Subjects:
T cells
Th17 & Tregs cells
multiple sclerosis
autoimmunity
retinoid X receptor (RXR)
retinoids
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.712241/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.712241/full

Similar Items